CTRI/2011/11/002154
Completed
Phase 3
Efficacy and safety of Baclofen GRS for treatment of alcohol dependence: A randomized, double blind, placebo controlled, comparative, parallel groups, multi-centric, 12-week study.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: F102- Alcohol dependenceHealth Condition 2: null- diagnosis of alcohol dependence
- Sponsor
- Sun Pharma Advanced Research Company Ltd
- Enrollment
- 195
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female subjects with age 21 to 75\-years inclusive, meeting DSM\-IV\-TRï?ª criteria for current alcohol dependence (per appendix I: M.I.N.I. for alcohol abuse and dependence) who are detoxified before enrollment in study. (subjects who have completed detoxification treatment can be enrolled)
- •2\.Presence of referred family member able to assist with drug administration and monitoring.
- •3\.Express a desire to achieve abstinence or to greatly reduce alcohol consumption.
- •4\.Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s) \[such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), oral or long acting injected contraceptives] from at least 2 months prior to study entry and through the duration of the study; or postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject); with a negative urine pregnancy test.
- •5\.Willing to participate and give written informed consent.
Exclusion Criteria
- •1\.Requiring inpatient detoxification and treatment with drugs other than single agent baclofen.
- •2\.Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 3 times the upper limit of normal.
- •3\.Bilirubin more than the upper limit of normal.
- •4\.Current treatment with naltrexone, disulfiram, acamprosate, topiramate, ondansetron: subjects can be included after appropriate washout.
- •5\.Positive urine screen on amphetamines/ barbiturates/ benzodiazepines/ cocaine/ opiates.
- •6\.Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, kidney impairment, unstable hypertension, hypotension, diabetes mellitus, seizure disorder).
- •7\.Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, or severe depression; suicidal ideation; substance use disorder other than alcohol or nicotine dependence. Subjects with ADHD/ ASPD may be included at discretion of the investigator.
- •8\.Current episode marked by/ current presentation of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens.
- •9\.Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics. Subjects who have been taking benzodiazepines for alcohol detoxification will be required to have a washout period of approximately 5 days from those medications before being randomized.
- •10\.Participation in another clinical trial within the preceding 60 days of study start.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Efficacy evaluation of oral baclofen treatment versus intrathecal baclofen in children with dystonic cerebral palsy - Oral/intrathecal therapy in children with dystoniaDystonic or spastic dystonic cerebral palsyMedDRA version: 9.1Level: SOCClassification code 10029205MedDRA version: 9.1Level: PTClassification code 10008129MedDRA version: 9.1Level: LLTClassification code 10021740EUCTR2008-000833-23-ITAZIENDA OSPEDALIERA ISTITUTI CLINICI DI PERFEZIONAMENTO DI MILANO
Recruiting
Phase 3
To examine how well Baclofen and Naltrexone work as medications in individuals with alcohol addiction and withdrawal symptoms.Health Condition 1: F102- Alcohol dependenceCTRI/2024/06/069491Rahul
Completed
N/A
Baclofen as relapse prevention in the treatment of Gamma-hydroxybutyrate (GHB) dependence: an open label study.NL-OMON39314Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results100
Recruiting
N/A
Baclofen as treatment for relapse in GHB abuseNL-OMON24379ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results100
Completed
Phase 1
The Efficacy of Baclofen to Treat Gastroesophageal Reflux disease in Children Aged 6 Months to 12 YearsGastroesophageal Reflux symptomTCTR20200415001Golestan University of Medical Sciences62